De Avila Jorge L, Meltzer David O, Zhang James X
Pritzker School of Medicine, The University of Chicago, Chicago, Illinois.
Department of Medicine, The University of Chicago, Chicago, Illinois.
JAMA Netw Open. 2021 Mar 1;4(3):e210498. doi: 10.1001/jamanetworkopen.2021.0498.
The unaffordability of drugs has been a persistent and elusive challenge in the US health care system. Little is known about the prevalence and persistence of cost-related medication nonadherence (CRN) in a population with high-cost, high-need resource utilization.
To evaluate the prevalence and persistence of CRN among Medicare beneficiaries at high risk of hospitalization as well as the characteristics associated with CRN in this population.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study used survey data from Medicare patients at high risk of hospitalization and with a life expectancy greater than 12 months at an urban academic medical center from November 6, 2012, to January 30, 2018. Patients were followed up for 12 months at 3-month intervals from baseline, for a total of 5 surveys. Data were analyzed from September 1, 2020, to January 5, 2021.
Self-reported CRN, using a metric of persistence and transiency. Based on the results of the 5 surveys, CRN was categorized as persistent (3 or more surveys), intermittent (2), transient (1), and any (1 or more). Multiple logistic regression analyses were used to evaluate factors associated with persistent and transient CRN.
Of the 1655 Medicare beneficiaries followed up during the 15-month study period, 1036 (62.6%) were women and 1452 (87.7%) were Black or African American; 769 (46.5%) were younger than 65 years, and 886 (53.5%) were 65 years or older (mean [SD] age, 62.4 [15.9] years). A total of 374 patients (22.6%) reported CRN at baseline, 810 (48.9%) reported any CRN, and 230 (13.9%) reported persistent CRN (148 [19.2%] of those younger than 65 years and 82 [9.3%] of those 65 years or older). The 230 patients who had persistent CRN accounted for 28% of those who reported CRN at least once during the 15-month study period. Younger age (eg, <50 years vs 75 years: adjusted odds ratio [AOR], 3.07; 95% CI, 1.61-5.86; P = .001), worse self-reported health (AOR, 1.59; 95% CI, 1.10-2.31; P = .01), and depression (AOR, 1.58; 95% CI, 1.11-2.24; P = .01) were associated with greater likelihood of persistent CRN. The population-adjusted prevalence of CRN was 53.6% (887 patients).
The findings suggest that CRN is prevalent, moderately persistent, and variable in the Medicare population at high risk of hospitalization despite coverage by insurance. Longitudinal follow-up and refined predictive modeling of CRN appear to be needed to identify and target more precisely those with persistent CRN and to develop effective interventions.
药品价格难以承受一直是美国医疗保健系统中一个长期存在且难以解决的挑战。对于高成本、高需求资源利用人群中与费用相关的药物治疗不依从(CRN)的患病率和持续性,人们了解甚少。
评估住院风险高的医疗保险受益人中CRN的患病率和持续性,以及该人群中与CRN相关的特征。
设计、设置和参与者:这项队列研究使用了2012年11月6日至2018年1月30日期间,在一家城市学术医疗中心对住院风险高且预期寿命超过12个月的医疗保险患者进行调查的数据。从基线开始,每3个月对患者进行一次为期12个月的随访,共进行5次调查。数据分析时间为2020年9月1日至2021年1月5日。
使用持续性和短暂性指标自我报告的CRN。根据5次调查结果,CRN分为持续性(3次或更多次调查)、间歇性(2次)、短暂性(1次)和任何情况(1次或更多次)。采用多因素逻辑回归分析评估与持续性和短暂性CRN相关的因素。
在15个月的研究期间随访的1655名医疗保险受益人中,1036名(62.6%)为女性,1452名(87.7%)为黑人或非裔美国人;769名(46.5%)年龄小于65岁,886名(53.5%)年龄在65岁及以上(平均[标准差]年龄,62.4[15.9]岁)。共有374名患者(22.6%)在基线时报告有CRN,810名(48.9%)报告有任何CRN情况,230名(13.9%)报告有持续性CRN(年龄小于65岁的患者中有148名[19.2%],年龄在65岁及以上的患者中有82名[9.3%])。在15个月的研究期间至少报告过一次CRN的患者中,有230名持续性CRN患者占28%。年龄较小(如,<50岁与75岁相比:调整后的优势比[AOR],3.07;95%置信区间,1.61 - 5.86;P = 0.001)、自我报告健康状况较差(AOR,1.59;95%置信区间,1.10 - 2.31;P = 0.01)以及患有抑郁症(AOR,1.58;95%置信区间,1.11 - 2.24;P = 0.01)与持续性CRN的可能性更大相关。CRN的人群校正患病率为53.6%(887名患者)。
研究结果表明,尽管有保险覆盖,但在住院风险高的医疗保险人群中,CRN普遍存在,具有中度持续性且存在差异。似乎需要对CRN进行纵向随访和完善的预测模型,以更精确地识别和针对持续性CRN患者,并制定有效的干预措施。